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1. Introduction
  Deep vein thrombosis (DVT) is the most common and 
serious complication after the major orthopedic surgery, 
which includes total hip replacement (THR), total knee 
replacement (TKR) and hip fractures surgery (HFS). Despite 
active anticoagulant therapy is given after the surgery, the 
fatality rate of the DVT can reached 3.8%, and the fatality 
rate of the pulmonary thromboembolism (PTE) can reached 
38.9%[1]. 
  Although compared to traditional anticoagulants, the new 
oral anticoagulant- rivaroxaban has advantages of safe dose 
rang and noninvasive administration, but the single mode of 
anticoagulation and unpredictable blood drug concentration 
is limiting its application. Ulinastatin, an acid glycoprotein 
which contained in the fresh urine of healthy humans, is 
well known to inhibit the activity of inflammation. The 
recent researches show that UTI could inhibit coagulation 
and fibrolysis by inhibiting the leukocyte activity. Therefore, 
the combination therapy of revaroxban and UTI perhaps 
advance the development of anticoagulant regiment.
2. Materials and methods
2.1. Participants and inclusion criteria
  After local ethics committee approval and written informed 
consent, 45 ASA 栺 or 栿 patients, aged 40-90 yr, scheduled 
for elective total hip replacement or hip fracture surgery, 
were enrolled in this study. Patients with such coexisting 
diseases or conditions as preoperative bleeding, clotting 
disorders, an abnormal coagulation test, thrombocytopenia, 
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and severe renal, hepatic or heart disease were excluded. 
Aspirin and other antiplatelet agents were discontinued 7 
days before the scheduled procedure.
  Patients were randomly divided into three groups: 
ulinastatin continuous infusion (Uc) group, ulinastatin single 
injection (Us) group and control (C) group.
2.2. Treatments
  After enter the operating room and before the anesthesia 
induction, Uc and Us group were premedicated with UTI 
5 000 U/kg[2], which was dissolved in normal saline 100 mL, 
Group C was given isometric normal saline. Spinal anesthesia 
was performed at the L2-L3 interspace as the patient in 
lateral position. All patients received a patient-controlled 
intravenous analgesia (PCIA) for 48 h postoperatively. The 
PCIA setting was as follows: background infusion fentanyl 
20 毺g/kg and ondansetron 8 mg, which was dissolved in NS 
to 100 mL, at a rate of 2 mL/h, bolus dose 0.5 mL, lockout 
inerval 15 min. The patients in Uc group were received UTI 
continuous infusion of 10 000 U/kg to 48 hours with the help 
of infusion pump. If visual analog scale (VAS) >3 in spite of 
treatment, a second dose of analgesic (fentanyl 0.05 mg) was 
given.
  All the operations were conducted by the same surgery 
and anesthesia team. All the patients took rivaroxaban 
10 mg orally 12 hours after the operation. Tests would be 
discontinued if the tendency of bleeding occurred.
2.3. Clinical evaluation and laboratory examination
  The operation time, blood loss and the infusion were 
recorded.
  Blood sample were obtained for analysis of Hematocrit 
(HCT), thrombomodulin (TM), Interleukin-6 (IL-6), thrombin-
antithrombin complex (TAT), D-Dimer (D-D) levels at 5 
intervals: before surgery (T1) , at the end of the surgery (T2) 
, 12 hours (T3) , 24 hours (T4), 48 hours (T5) after the surgery. 
HCT were detected with hematology analyzer (SysmexXE-
2100). Serum IL-6, TAT, D-D, TM concentrations were 
assayed by ELISA (R&D company, America). 
2.4. Statistical analysis
  Statistical analysis was performed with the 氈
2 test of 
the sex and type of surgery. One-way factorial analysis of 
variance (ANOVA) was used in analysis of other demographic 
data. P value <0.05 was considered as statistically significant 
difference.
3. Results
3.1. General observation
  The general data compared with treatment group and 
control group as follows (Table 1), and there was no 
significantly differences (P>0.05) in sex, age, type of surgery, 
etc. No significant change of the HCT was found between 
three groups in each time point, which excluded the effect of 
blood dilution on the experimental results (Table 2).
Table 1
Comparison of background variables.
Issues Uc Us C
Sex (M/F) 8/7 9/6 8/7
Age   68.27依13.26   69.80依11.97      66.73依13.89
BMI   22.31依1.55   21.92依1.47      21.51依1.60
Type (THR/HFS) 11/4 12/3 11/4
OR time(min)   79.00依23.69   80.33依28.31      80.33依26.35
Blood loss(mL) 124.00依61.04 150.67依78.96    142.33依72.97
Infusion(mL) 973.33依187.91 923.33依273.77 1 093.33依405.26
Table 2
Changes of hematocrit in three groups (n=15, %, mean依sd).
Indexes Uc Us C
HCT T1 38.31依3.93 36.34依4.75 38.36依3.65
T2 33.75依4.38 31.63依4.32 33.37依3.30
T3   34.3依5.66   33.5依5.77 33.30依3.17
T4 32.42依5.93 31.57依3.36 32.25依3.27
T5 30.91依5.50 29.76依3.24 30.85依2.52
3.2. TM scores
  As shown in Table 3, TM score was gradually increased 
in C group till 48 hours after the surgery (P<0.05). However, 
it was declined in Uc group (P<0.05). The TM score was 
significantly increase 24 hours after single injection (P<0.05). 
3.3. IL-6 scores     
  As shown in Table 4, after the surgery, both ulinastatin 
single injection group and ulinastatin continuous infusion 
group showed no conspicuous change in IL-6 (P>0.05). 
However, the level of IL-6 in control group was significantly 
increased (P<0.05). But 24 hours after single injection, the 
IL-6 score in Uc group were significant increase as in C 
group (P<0.05). No outstanding change was observed in Uc 
group till 48 hours after the surgery (P>0.05).
Table 3
Changes of TM in three groups (n=15,毺g/L, mean依sd).
Groups T1 T2 T3 T4 T5
Uc   47.36依15.07   40.42依9.37●▲    40.60依8.80●▲    34.82依6.19●▲      43.98依13.14●▲
Us   41.93依11.42 42.35依8.45● 44.18依8.98●   50.50依14.33▲ 57.00依9.52▲
C 44.33依8.00 51.62依7.66▲ 53.86依7.47▲ 54.72依8.47▲ 57.10依8.31▲
●Compared with group C, P<0.05; ▲ Compared with T1, P<0.05.
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3.4. TAT scores
  From Table 5, it showed that TAT exhibited roughly 
increasing tendency after the surgery for 48 hours in C 
group (P<0.05), However, Uc group and Us group showed no 
significant changes (P>0.05). 
3.5. D-D scores
  As shown in Table 6, 12 hours after the surgery, no 
remarkable changes was found in D-D serous concentration 
of both Ulinastatin single injection group and ulinastatin 
continuous infusion group (P>0.05). Nevertheless, the 
control group showed very significant increase in D-D 
level (P<0.05). Also after 12 hours, D-D concentration in Uc 
group was significantly lower than that of C group (P<0.05). 
Although the D-D level in Us group was higher compared 
with C group (P<0.05), and no significant difference was 
observed (P>0.05). 
3.6. Comparison of clinical adverse reaction
  Both three groups showed no hemorrhagic tendency.
4. Discussion
  Patients with trauma and orthopedic surgery can cause 
local tissue swelling, inflammation infiltration, endothelial 
cells damage at the same time, which promote the blood 
platelet aggregation and adhesion. In perioperative 
period the restrict mobility, the using of bone cement and 
tourniquet in the surgery, and general anesthesia, obesity, 
etc, are all risk factors for DVT occurred[3,4]. Once DVT was 
diagnosed from imageology, it is hard to be cured. So the 
early prophylaxis and discovery of thrombophilia is the key 
to prevent DVT.
  Previous studies showed that low molecular heparin 
injected subcutaneously could be used to prevent and cure 
DVT effectively. Meanwhile, the potent anticoagulant effect 
could cause bleeding tendency, and it is one typical side 
effect. Moreover, the way of invasive administration reduces 
the clinical compliance of patients. Recently, it has been 
reported that one kind of new oral anticoagulant rivaroxaban 
is replacing its anticoagulation status gradually as a result 
of simple and noninvasive application. Rivaroxaban plays 
a role in restraining the process of blood coagulation as a 
kind of highly selective Fxa inhibitor, and it has been widely 
used in clinic currently. But there are some scruples with its 
using process, for example, the drug lacks of individualized 
treatment plan[5], and it still induces bleeding tendency[6]. 
  Ulinastatin, an acid glycoprotein which was contained 
in the fresh urine of healthy humans, is well known to 
inhibit the activity of inflammation. The recent researches 
showed that UTI could inhibit coagulation and fibrolysis 
by inhibiting the leukocyte activity[7]. This function is 
very important in regulating coagulation system. So it is 
hypothesized that Ulinastatin may take effect on preventing 
DVT.
  Because of this, during the treatment, we especially 
emphasize on changing patients’ hypercoagulabale state, 
not just aim to theirs’ single anticoagulation function. The 
treatment target is to improve patients’ medication safety by 
assisting in regulating the coagulation system.
  The results in this study suggest that the combination of UTI 
and rivaroxaban can significantly decrease the incidence of 
postoperative DVT as detection by laboratory examination. 
Even in those patients with the highest tendency to develop 
Table 4
Changes of IL-6 in three groups (n=15, ng/L, mean依sd)
Groups T1 T2 T3 T4 T5
Uc   478.82依124.01 468.86依112.99    455.24依84.37● 493.31依66.12● 499.26依107.78●
Us   538.09依162.15 537.71依122.96 585.67依87.92    641.45依111.81▲ 635.61依101.65▲
C 471.83依69.12    528.50依114.09▲      546.35依102.79▲ 574.47依93.21▲ 601.32依150.73▲
●Compared with group C, P<0.05; ▲ Compared with T1, P<0.05.
Table 5
Changes of TAT in three groups (n=15, ng/L, mean依sd).
Groups T1 T2 T3 T4 T5
Uc 640.95依120.73 620.34依73.38 577.86依94.73● 632.43依97.47●    644.06依120.21●
Us 636.99依87.23 639.55依61.93 617.04依49.63 675.41依109.81 710.31依113.13
C 605.91依67.11 693.63依121.11▲ 664.35依86.78▲ 752.56依100.95▲  736.97依71.15▲
●Compared with group C, P<0.05; ▲ Compared with T1, P<0.05.
Table 6
Changes of D-D in three groups (n=15,毺g/L, mean依sd).
Groups T1 T2 T3 T4 T5
Uc 763.91依121.34 763.30依176.93   729.28依151.75●    656.90依176.05●    705.69依193.90●
Us 760.32依112.21 799.80依121.28   877.62依152.11▲ 1 008.53依250.67▲ 1 141.09依218.54▲
C 764.37依129.71    881.75依132.10▲ 870.60依97.17▲    938.17依110.67▲ 1 065.70依145.44▲
●Compared with group C, P<0.05; ▲ Compared with T1, P<0.05.
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thrombosis, such as elderly patients having major orthopedic 
operations. There was no complication occurrence after 
administrating the drugs. 
  Previously, Virchow stated that venous thrombosis was 
caused by changes in one or more of three important 
factors- blood flow, venous endothelium, and the clotting 
mechanism[8]. And “Virchow’s triad” is of prime importance 
in the prevention of thrombosis.
  In our experiment, though rivaroxaban was routinely given 
for anticoagulation therapy postoperatively in C group, a 
rising curve of L-6, TAT, D-D and TM occurred and lasted 
from the completion of the surgery to 48 hours after the 
surgery. UTI can inhibit the rise of these parameters. This 
finding was consistent with those of several precious reports.
Sympathetic excitation and further vasoconstriction resulted 
from Trauma and surgery, the use of alkaline anesthetics, 
the ischemia-reperfusion injury caused by tourniquet are all 
considered to play a part in the endothelial cells disorder. 
TM, a type of membrane receptor locating on the surface of 
vascular endothelial cells, would be released into the blood 
when the cell was damaged. This experiment suggests that 
UTI has a role on protecting endothelial cell and contrarily 
less role effect on rivaroxaban; in single injection group, 
endothelial cells are observed to start damaging 24 hours 
after the surgery. The primary mechanisms of the UTI on the 
protection of endothelial cells may not only depending on 
inhibiting the activity of elastase secreted by neutrophils, 
but also directly inhibit the secretion of the enzyme itself[9].
  TAT is induced by thrombin and has a rapid turnover. 
Thus, it is a sensitive parameter of the latent activation 
of the clotting pathway. The rise of TAT suggests that the 
thrombin is generating and the antithrombin is being 
depleted continuously. So TAT is the direct evidence of the 
activation of promoting coagulation and the consumption of 
inhibitor. As we all know, there are reciprocating relations 
between thrombosis and inflammation. In our study, the 
level of IL-6 was significantly increased after the surgery 
till 2 days in C group, but the same changes of IL-6 was 
not observed in UTI group. It was demonstrated that the 
enhancement of IL-6 had been inhibited by UTI. Similarly, 
TAT could increase with the surgery only using rivaroxaban, 
and UTI could inhibit this augmentation. The mechanism of 
UTI on coagulation system is mainly through the intrinsic 
coagulation pathway, the Kunitz structural domain of UTI 
can influence the coagulation factors, especially the activity 
of factor X[10].
  D-dimer is a kind of small protein fragment presented 
in the blood after the blood clot degraded by fibrinolysis. 
Hence, its increase in blood indicates the progression of 
fibrinolysis. 10 000 U/kg UTI can reduce the D-D in patients 
who undergoing hip joint replacement[11]. The results in 
our research showed that 5伊104U/kg UTI has effect on 
fibrinolytic system in human, while the effect of single 
injection can only last less than 12 hours on D-dimer. 
However, Rivaroxaban has no such an effect.
  Our experiment excluded the influence of the blood 
dilution by testing HCT. So there was no significant 
difference in the blood flow in and between three groups.
  Although different studies were designed to investigate 
the low molecular fragment originated from active 
pharmacological reaction still have effect, this suggests 
that in theory, if single dose of UTI was administered at the 
beginning of the surgery, the effect would maintain for a long 
time[12]. In this experiment, the results show that the effect 
of UTI just lasted for 12-24 hours if single injection, while 
all the investigated indices were kept stable in condition 
of continuous injection of UTI. It means that UTI combined 
with rivaroxaban is a satisfactory method of preventing the 
DVT.
  In this study, we explored the effect of combined UTI 
with rivaroxaban on preventing DVT. The conclusion was 
drawn that the combination of UTI and Rivaroxaban was 
more effective than using rivaroxaban only, and it is also 
important for UTI to be intravenously injected continuously. 
However, this study is lack of large-scale and multicenter 
clinical verification. Moreover, we just observed the changes 
of indices in 48 hours after the surgery. Thus, further 
studies are still needed to search for a reasonable drug 
administration time and the suitable dosage.
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